Replies to post #220529 on Biotech Values

[DewDiligence]

ABBV/ENTA/GILD—Mavyret’s US new-patient share=51.7%—tied for the highest-ever weekly figure—in the week ending 9/28/18, as reported by IMS. GILD’s US new-patient share was 47.2%, and MRK’s was 1.1%.

Mavyret’s US total-script share reached 47.5% in the week ending 9/28/18, the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 51.3%, and MRK’s was 1.2%.